March 16, 2023
5 min watch
Save
VIDEO: FORMULA-509 probes salvage radiation and gonadotropin-releasing hormone regimen
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Cancer Institute, discusses the FORMULA-509 trial he co-presented at ASCO Genitourinary Cancers Symposium.
The study examined patients with a rising PSA after radical prostatectomy who had at least one unfavorable risk factor, and who received salvage radiation and 6 months of a gonadotropin-releasing hormone agonist.
“What I think we can say now is for a patient today, using the FORMULA-509 regimen is a very attractive alternative to having to lengthen the duration of hormone therapy to 24 months,” Nguyen said.
Reference:
- Nguyen P, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). Presented at: ASCO Genitourinary Cancers Symposium; ; Feb. 16-18, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Nguyen reports consulting for Bayer, Blue Earth Diagnostics, Boston Scientific, Janssen Oncology and Myovant Sciences; and receiving research funding from Astellas Pharma, Bayer and Janssen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.